Brokerages Set Xencor, Inc. (NASDAQ:XNCR) PT at $24.38

Xencor, Inc. (NASDAQ:XNCR) has earned an average recommendation of “Moderate Buy” from the nine analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $24.3750.

Several brokerages recently weighed in on XNCR. Wall Street Zen upgraded Xencor from a “sell” rating to a “hold” rating in a report on Saturday, April 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research report on Friday, March 27th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $13.00 target price (down from $18.00) on shares of Xencor in a research note on Tuesday, March 24th. Finally, Barclays lifted their price target on shares of Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th.

Insider Activity at Xencor

In other news, SVP Celia Eckert sold 3,244 shares of the stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $11.25, for a total value of $36,495.00. Following the completion of the sale, the senior vice president owned 78,685 shares of the company’s stock, valued at approximately $885,206.25. This represents a 3.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP John R. Desjarlais sold 2,502 shares of the company’s stock in a transaction on Friday, March 6th. The stock was sold at an average price of $11.02, for a total transaction of $27,572.04. Following the sale, the vice president directly owned 263,831 shares in the company, valued at $2,907,417.62. This trade represents a 0.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 44,020 shares of company stock valued at $499,817. 5.23% of the stock is owned by corporate insiders.

Institutional Trading of Xencor

Hedge funds have recently made changes to their positions in the business. Principal Financial Group Inc. increased its holdings in shares of Xencor by 2.0% in the first quarter. Principal Financial Group Inc. now owns 347,078 shares of the biopharmaceutical company’s stock valued at $4,186,000 after purchasing an additional 6,752 shares during the last quarter. Fifth Third Bancorp boosted its holdings in shares of Xencor by 3,690.2% during the 1st quarter. Fifth Third Bancorp now owns 17,018 shares of the biopharmaceutical company’s stock worth $205,000 after buying an additional 16,569 shares during the period. Hsbc Holdings PLC raised its holdings in Xencor by 179.4% in the 1st quarter. Hsbc Holdings PLC now owns 58,579 shares of the biopharmaceutical company’s stock valued at $717,000 after acquiring an additional 37,610 shares during the period. Inspire Investing LLC lifted its position in Xencor by 38.6% during the first quarter. Inspire Investing LLC now owns 42,529 shares of the biopharmaceutical company’s stock worth $513,000 after acquiring an additional 11,853 shares during the last quarter. Finally, Louisiana State Employees Retirement System bought a new stake in shares of Xencor during the first quarter worth approximately $382,000.

Xencor Stock Down 3.8%

NASDAQ XNCR opened at $12.85 on Wednesday. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.25 and a quick ratio of 6.25. The firm has a market cap of $952.57 million, a PE ratio of -10.36 and a beta of 0.93. The stock’s 50 day simple moving average is $12.24 and its 200 day simple moving average is $13.63. Xencor has a one year low of $6.92 and a one year high of $18.69.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.55. Xencor had a negative net margin of 73.20% and a negative return on equity of 14.58%. The business had revenue of $28.24 million during the quarter, compared to analyst estimates of $29.97 million. During the same quarter last year, the business posted ($0.62) earnings per share. Xencor’s revenue for the quarter was down 46.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Xencor will post -2.87 earnings per share for the current fiscal year.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.